Shanghai Henlius Biotech, Inc. (2696.HK)
2696.HK Stock Price Chart
Explore Shanghai Henlius Biotech, Inc. interactive price chart. Choose custom timeframes to analyze 2696.HK price movements and trends.
2696.HK Company Profile
Discover essential business fundamentals and corporate details for Shanghai Henlius Biotech, Inc. (2696.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Sept 2019
Employees
3.52K
Website
https://www.henlius.comCEO
Jun Zhu
Description
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2696.HK Financial Timeline
Browse a chronological timeline of Shanghai Henlius Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 20 May 2025
Earnings released on 24 Mar 2025
EPS came in at $0.42 , while revenue for the quarter reached $1.58B .
Earnings released on 15 Nov 2024
EPS came in at $0.44 , while revenue for the quarter reached $1.65B .
Earnings released on 26 Aug 2024
EPS came in at $0.38 , while revenue for the quarter reached $1.47B .
Earnings released on 20 May 2024
EPS came in at $0.38 , while revenue for the quarter reached $1.49B .
Earnings released on 21 Mar 2024
EPS came in at $0.28 , while revenue for the quarter reached $1.62B , missing expectations by -73.73%.
Earnings released on 15 Nov 2023
EPS came in at $0.33 , while revenue for the quarter reached $1.53B .
Earnings released on 25 Aug 2023
EPS came in at $0.24 , while revenue for the quarter reached $1.35B .
Earnings released on 1 Apr 2023
EPS came in at -$0.74 , while revenue for the quarter reached $1.23B , missing expectations by -66.40%.
Earnings released on 31 Mar 2023
EPS came in at $0.25 , while revenue for the quarter reached $1.43B .
Earnings released on 30 Sept 2022
EPS came in at -$0.18 , while revenue for the quarter reached $928.05M .
Earnings released on 18 Aug 2022
EPS came in at -$0.29 , while revenue for the quarter reached $794.53M , missing expectations by -67.92%.
Earnings released on 30 Jun 2022
EPS came in at -$0.27 , while revenue for the quarter reached $754.72M .
Earnings released on 31 Dec 2021
EPS came in at -$0.67 , while revenue for the quarter reached $642.10M .
Earnings released on 30 Sept 2021
EPS came in at -$0.66 , while revenue for the quarter reached $632.55M .
Earnings released on 30 Jun 2021
EPS came in at -$0.44 , while revenue for the quarter reached $380.36M .
Earnings released on 31 Mar 2021
EPS came in at -$0.43 , while revenue for the quarter reached $375.14M .
Earnings released on 31 Dec 2020
EPS came in at -$0.61 , while revenue for the quarter reached $283.36M .
Earnings released on 30 Sept 2020
EPS came in at -$0.58 , while revenue for the quarter reached $272.05M .
2696.HK Stock Performance
Access detailed 2696.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.